 Aim 1 investigates the impact of amyloid PET on short-term patient management, by comparing pre-PET intended management ascertained in a case report form CRF prior to PET to post-PET actual management 90-days post-PET. The primary objective will be to test whether amyloid PET leads to a 30 change between intended and actual patient management within 90 days in a cumulative endpoint consisting of: Alzheimers disease AD drug therapy, other drug therapy, and counseling about safety and future planning. Secondary objectives will assess the impact of amyloid PET results on clinical diagnosis and prevention of unnecessary diagnostic procedures and treatments. 